BRPI0618493A2 - composições farmacêuticas e usos das mesmas para o tratamento de distúrbios do snc - Google Patents

composições farmacêuticas e usos das mesmas para o tratamento de distúrbios do snc Download PDF

Info

Publication number
BRPI0618493A2
BRPI0618493A2 BRPI0618493-6A BRPI0618493A BRPI0618493A2 BR PI0618493 A2 BRPI0618493 A2 BR PI0618493A2 BR PI0618493 A BRPI0618493 A BR PI0618493A BR PI0618493 A2 BRPI0618493 A2 BR PI0618493A2
Authority
BR
Brazil
Prior art keywords
treatment
pharmaceutical compositions
disorders
snc
snc disorders
Prior art date
Application number
BRPI0618493-6A
Other languages
English (en)
Inventor
Dale S Dhanoa
Oren M Becker
Silvia Noiman
Pradyumna Mohanty
Dongli Chen
Mercedes Lobera
Laurence Wu
Yael Marantz
Boaz Inbal
Alexander Heifetz
Shay Bar-Haim
Sharon Shacham
Original Assignee
Epix Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epix Pharm Inc filed Critical Epix Pharm Inc
Publication of BRPI0618493A2 publication Critical patent/BRPI0618493A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSIçõES FARMACêUTICAS E USOS DAS MESMAS PARA O TRATAMENTO DE DISTúRBIOS DO SNC. A invenção refere-se em geral a moduladores do receptor tieno-piridinona 5-HT~4~ e, em particular, ao uso desses compostos e suas composições farmacêuticas, por exemplo, no tratamento, modulação e/ou prevenção de condições fisiológicas associadas com ação de serotonina, tal como no tratamento de doença de Alzheimer, distúrbios cognitivos, depressão e ansiedade.
BRPI0618493-6A 2005-11-10 2006-11-06 composições farmacêuticas e usos das mesmas para o tratamento de distúrbios do snc BRPI0618493A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/271,019 US7598265B2 (en) 2004-09-30 2005-11-10 Compositions and methods for treating CNS disorders
PCT/US2006/043140 WO2007058805A2 (en) 2005-11-10 2006-11-06 Compositions and methods for treating cns disorders

Publications (1)

Publication Number Publication Date
BRPI0618493A2 true BRPI0618493A2 (pt) 2011-08-30

Family

ID=37946751

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0618493-6A BRPI0618493A2 (pt) 2005-11-10 2006-11-06 composições farmacêuticas e usos das mesmas para o tratamento de distúrbios do snc

Country Status (17)

Country Link
US (2) US7598265B2 (pt)
EP (1) EP1959954A2 (pt)
JP (1) JP2009515877A (pt)
KR (1) KR20080067001A (pt)
CN (1) CN101340908A (pt)
AR (1) AR057887A1 (pt)
AU (1) AU2006315854A1 (pt)
BR (1) BRPI0618493A2 (pt)
CA (1) CA2629312C (pt)
CR (1) CR10062A (pt)
EA (1) EA200801302A1 (pt)
IL (1) IL191168A0 (pt)
MA (1) MA30037B1 (pt)
NO (1) NO20082679L (pt)
TW (1) TW200735868A (pt)
WO (1) WO2007058805A2 (pt)
ZA (1) ZA200804951B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612078B2 (en) * 2003-03-31 2009-11-03 Epix Delaware, Inc. Piperidinylamino-thieno[2,3-D] pyrimidine compounds
US20050222175A1 (en) * 2004-03-31 2005-10-06 Dhanoa Dale S New piperidinylamino-thieno[2,3-D] pyrimidine compounds
US7488736B2 (en) * 2004-05-17 2009-02-10 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
US7576211B2 (en) * 2004-09-30 2009-08-18 Epix Delaware, Inc. Synthesis of thienopyridinone compounds and related intermediates
US7407966B2 (en) * 2004-10-07 2008-08-05 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
US7598265B2 (en) * 2004-09-30 2009-10-06 Epix Delaware, Inc. Compositions and methods for treating CNS disorders
CA2595607C (en) * 2005-01-25 2014-07-15 Epix Delaware, Inc. Substituted arylamine compounds and their use as 5-ht6 modulators
GB0526258D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
WO2010065743A2 (en) * 2008-12-03 2010-06-10 Nanotherapeutics, Inc. Bicyclic compounds and methods of making and using same
JP2012523437A (ja) * 2009-04-13 2012-10-04 セラヴァンス， インコーポレーテッド 認知障害の治療のための５−ｈｔ４受容体アゴニスト化合物
WO2022169973A1 (en) * 2021-02-04 2022-08-11 Natrillo Richard Dietary supplement for improving brain performance

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3069412A (en) * 1958-08-15 1962-12-18 Fmc Corp N-aminoazetidine and preparation thereof
CA933923A (en) * 1969-12-19 1973-09-18 Eichenberger Kurt Process for the manufacture of new thiopyranes
GB1570494A (en) * 1975-11-28 1980-07-02 Ici Ltd Thienopyrimidine derivatives and their use as pesticides
DE2925175A1 (de) * 1979-06-22 1981-01-08 Basf Ag Verfahren zur herstellung von isatosaeureanhydriden
IT1203323B (it) 1987-02-02 1989-02-15 Hoechst Italia Spa Additivo fotoattivatore per composizioni polimeriche costituito dal sale metallico di una cera ossidata
US5236917A (en) * 1989-05-04 1993-08-17 Sterling Winthrop Inc. Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
DE4008726A1 (de) 1990-03-19 1991-09-26 Basf Ag Thieno(2,3-d)pyrimidinderivate
DE4023270A1 (de) * 1990-07-21 1992-02-06 Hoechst Ag Hydrophile mischpolymere sowie deren verwendung in der reprographie
US5155115A (en) * 1991-03-12 1992-10-13 Kyowa Hakko Kogyo Co., Ltd. Thienopyridine derivatives
US5219864A (en) 1991-03-12 1993-06-15 Kyowa Hakko Kogyo Co., Ltd. Thienopyridine derivatives
US5227387A (en) * 1991-09-03 1993-07-13 Dowelanco Quinoline nematicidal method
DE4138820A1 (de) * 1991-11-26 1993-05-27 Basf Ag Chinolin-3-carbonsaeureamide, deren herstellung und verwendung
DE4208254A1 (de) * 1992-03-14 1993-09-16 Hoechst Ag Substituierte pyrimidine, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel und fungizid
DE4227747A1 (de) * 1992-08-21 1994-02-24 Basf Ag Heteroaromatisch kondensierte Hydroxypyridoncarbonsäureamide, deren Herstellung und Verwendung
US5409948A (en) 1992-11-23 1995-04-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method for treating cognitive disorders with phenserine
JPH06239858A (ja) * 1993-02-16 1994-08-30 Otsuka Pharmaceut Co Ltd 末梢血管拡張剤
GB9306460D0 (en) 1993-03-29 1993-05-19 Smithkline Beecham Plc Novel compounds
JPH07324087A (ja) * 1994-04-04 1995-12-12 Taisho Pharmaceut Co Ltd 複素環化合物
TW449600B (en) * 1994-04-19 2001-08-11 Takeda Chemical Industries Ltd Condensed-ring thiophene derivatives, their production and use
JP3829879B2 (ja) * 1994-05-18 2006-10-04 大正製薬株式会社 キノリンカルボン酸誘導体
GB2295387A (en) 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
DE19636769A1 (de) * 1996-09-10 1998-03-12 Basf Ag 3-Substituierte Pyrido [4',3':4,5]thieno[2,3-d]pyrimidin-Derivate, ihre Herstellung und Verwendung
US6979309B2 (en) * 1997-02-14 2005-12-27 Nxstage Medical Inc. Systems and methods for performing blood processing and/or fluid exchange procedures
DE19724980A1 (de) * 1997-06-13 1998-12-17 Basf Ag 3-Substituierte 3,4-Dihydro-thieno[2,3-d]pyrimidin-Derivate, ihre Herstellung und Verwendung
JPH11130777A (ja) 1997-08-13 1999-05-18 Takeda Chem Ind Ltd チエノピリジン誘導体、その中間体およびそれらの製造法
ATE404539T1 (de) * 1997-10-02 2008-08-15 Eisai R&D Man Co Ltd Kondensierte pyridinderivate
US6103903A (en) * 1998-02-26 2000-08-15 Neurogen Corporation 4-(4-piperidylmethyhlamino) substituted heteroaryl fused pyridines: GABA brain receptor ligands
DE19815026A1 (de) * 1998-04-03 1999-10-07 Hoechst Schering Agrevo Gmbh Substituierte Piperidine, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide
WO1999051932A2 (en) * 1998-04-08 1999-10-14 Moshier Gary S Launched munition neutralization of buried mines
NZ508314A (en) * 1998-06-02 2004-03-26 Osi Pharm Inc Pyrrolo[2,3d]pyrimidine compositions and their use
US6232320B1 (en) * 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
CN1461216A (zh) 1999-04-28 2003-12-10 呼吸器有限公司 用作治疗有关支气管收缩的机能障碍的药物的化合物
SE9902987D0 (sv) 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
WO2001025218A1 (fr) 1999-10-01 2001-04-12 Japan Energy Corporation Nouveaux derives de quinazoline
EP1270568A1 (en) 2001-06-19 2003-01-02 Biofrontera Pharmaceuticals AG 1-methyl-4-(3-ethoxy-9h-thioxanthene-ylidene)-piperidine and its use as 5-HT2B and/or H1 antagonist
WO2003020728A1 (en) * 2001-08-30 2003-03-13 Pharmacia & Upjohn Company 4-THIOXO-4,7-DIHYDRO-THIENO[2,3-b]PYRIDINE-5-CARBOTHIOAMIDES AS ANTIVIRAL AGENTS
MXPA03000145A (es) 2002-01-07 2003-07-15 Pfizer Compuestos de oxo u oxi-piridina como moduladores de receptores 5-ht4.
AU2003298514A1 (en) 2002-05-17 2004-05-04 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
US20040138238A1 (en) * 2002-08-08 2004-07-15 Dhanoa Dale S. Substituted aminopyrimidine compounds as neurokinin antagonists
AU2003255845A1 (en) 2002-08-22 2004-03-11 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
AU2003277215A1 (en) 2002-10-01 2004-04-23 Predix Pharmaceuticals Holdings, Inc. Novel neurokinin antagonists and methods of use thereof
US7153858B2 (en) * 2003-01-31 2006-12-26 Epix Delaware, Inc. Arylpiperazinyl compounds
NZ542236A (en) * 2003-03-31 2008-05-30 Predix Pharmaceuticals Holding New piperidinylamino-thieno[2,3-d]pyrimidine compounds
US20050222175A1 (en) * 2004-03-31 2005-10-06 Dhanoa Dale S New piperidinylamino-thieno[2,3-D] pyrimidine compounds
US7612078B2 (en) * 2003-03-31 2009-11-03 Epix Delaware, Inc. Piperidinylamino-thieno[2,3-D] pyrimidine compounds
US7119205B2 (en) * 2003-05-16 2006-10-10 Abbott Laboratories Thienopyridones as AMPK activators for the treatment of diabetes and obesity
DE602004009195T2 (de) * 2003-07-25 2008-06-26 F. Hoffmann-La Roche Ag Kombination eines mglur2 antagonists und eines ache inhibitors zur behandlung von akuten und/oder chronischen neurologischen krankheiten
GB0322140D0 (en) * 2003-09-22 2003-10-22 Pfizer Ltd Combinations
EP2338490A3 (en) * 2003-11-03 2012-06-06 Probiodrug AG Combinations useful for the treatment of neuronal disorders
US7488736B2 (en) * 2004-05-17 2009-02-10 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
US20060084806A1 (en) * 2004-07-21 2006-04-20 Ramasubramanian Sridharan Processes for the preparation of imidazo[1,2-a] pyridine derivatives
US7407966B2 (en) 2004-10-07 2008-08-05 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
US7598265B2 (en) 2004-09-30 2009-10-06 Epix Delaware, Inc. Compositions and methods for treating CNS disorders
US7576211B2 (en) 2004-09-30 2009-08-18 Epix Delaware, Inc. Synthesis of thienopyridinone compounds and related intermediates
CA2595607C (en) * 2005-01-25 2014-07-15 Epix Delaware, Inc. Substituted arylamine compounds and their use as 5-ht6 modulators
WO2007061458A2 (en) * 2005-11-23 2007-05-31 Epix Delaware, Inc. S1p receptor modulating compounds and use thereof
AR061637A1 (es) 2006-06-26 2008-09-10 Epix Delaware Inc Composiciones y metodos de tratamiento de trastornos del snc
WO2008045558A2 (en) 2006-10-12 2008-04-17 Epix Delaware, Inc. Benzothiadiazine compounds and their use
WO2008060632A2 (en) 2006-11-17 2008-05-22 Epix Delaware, Inc. Adenosine analogs and their use

Also Published As

Publication number Publication date
EP1959954A2 (en) 2008-08-27
CA2629312C (en) 2014-08-12
AU2006315854A1 (en) 2007-05-24
ZA200804951B (en) 2009-04-29
IL191168A0 (en) 2008-12-29
TW200735868A (en) 2007-10-01
MA30037B1 (fr) 2008-12-01
CR10062A (es) 2009-05-14
CA2629312A1 (en) 2007-05-24
CN101340908A (zh) 2009-01-07
US7598265B2 (en) 2009-10-06
WO2007058805A3 (en) 2007-10-04
WO2007058805A2 (en) 2007-05-24
JP2009515877A (ja) 2009-04-16
NO20082679L (no) 2008-06-10
US20060234998A1 (en) 2006-10-19
AR057887A1 (es) 2007-12-26
US20110195953A1 (en) 2011-08-11
KR20080067001A (ko) 2008-07-17
EA200801302A1 (ru) 2009-02-27

Similar Documents

Publication Publication Date Title
BRPI0618493A2 (pt) composições farmacêuticas e usos das mesmas para o tratamento de distúrbios do snc
TW200612926A (en) Compounds and compositions as ppar modulators
MX2007009356A (es) Compuestos y composiciones como moduladores de ppar.
MA31764B1 (fr) Composés et compositions en tant que modulateurs de l'activité de gpr119
WO2007089557A3 (en) Polycyclic 1, 2, 3, 4 -tetrahydro- isoquinoline derivatives and compositions comprising them as ppar modulators
BR0313676A (pt) Derivados de pirimidina e uso destes como moduladores cb2
BRPI0607017B8 (pt) composição farmacêutica compreendendo memantina e donezepil, e seu uso para o tratamento de condições relacionadas ao snc
BRPI0607562A2 (pt) derivados da diosmetina para o tratamento e a prevenção das patologias trombóticas
DE602007002792D1 (de) Verbindungen und zusammensetzungen als ppar-modulatoren
TW200612905A (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
MY147767A (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
TW200738724A (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
PL2134704T3 (pl) Związki i kompozycje pełniące rolę modulatorów aktywności GPR119
WO2007100366A3 (en) Quinolone m1 receptor positive allosteric modulators
CL2007003326A1 (es) Compuestos derivados de pirrol[2,3-b]piridina, moduladores de la actividad del c-fms y/o el c-kit; composicion farmaceutica; y uso para el tratamiento de tumores de celulas mamarias, asma, artritis reumatoide, enfermedad de parkinson, entre otras.
TNSN07376A1 (en) Npy antagonists, preparation and use
GT200500137A (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis.
WO2007056366A3 (en) Compounds and compositions as ppar modulators
TW200600505A (en) Compounds and compositions as ppar modulators
BRPI0508051A (pt) derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes
TW200611695A (en) Pyrrolopyridine derivatives
UY31346A1 (es) Compuestos que tienen actividad en el receptor m1 y sus usos en medicina
WO2008153937A3 (en) Novel 1- heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
CL2008002480A1 (es) Compuestos derivados de 3-(4-aminofenil)-metil-4-hidroxi-5-amino-tiopirano, inhibidores de beta-secretasa bace; procedimiento de preparacion; composicion farmaceutica; combinacion farmaceutica, y su uso en el tratamiento de trastornos neurologicos o vaaculares, tal como la enfermedad de alzheimer, sindrome de down y deterioro de la memoria.
IL189974A0 (en) Benzimidazole derivatives and their use for modulating the gabaa receptor complex

Legal Events

Date Code Title Description
B25C Requirement related to requested transfer of rights

Owner name: EPIX PHARMACEUTICALS, INC. (US)

Free format text: A FIM DE ATENDER A TRANSFERENCIA, REQUERIDA ATRAVES DA PETICAO NO 860150191136 DE 27/08/2015, E NECESSARIO ESCLARECER A DIVERGENCIA ENTRE A EMPRESA TITULAR DO PEDIDO E A CEDENTE.

B25B Requested transfer of rights rejected

Owner name: EPIX PHARMACEUTICALS, INC. (US)

B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: A PETICAO DE NO 870170003234, APRESENTADA EM 17/01/2017, E CONSIDERADA COMO PETICAO NAO CONHECIDA, UMA VEZ QUE A PETICAO QUE SOLICITOU A TRANSFERENCIA FOI INDEFERIDA.

B25A Requested transfer of rights approved

Owner name: NANOTHERAPEUTICS, INC. (US)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2435 DE 05-09-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.